Tresiba® and Ryzodeg® receive marketing authorisations in Europe
2013-01-21 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 21 January 2013 - Novo Nordisk today announced that the European Commission has granted marketing authorisations for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) for the treatment of diabetes in adults. The authorisations cover all 27 European Union member states. Further information Media: Mike Rulis +45 4442 3573 [email protected] Ambre Morley (US) +1 609 216 5240 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 6 / 2013
The release as fetched from its publisher. novonordisk.com ↗